Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
NCT03592641 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 25, 2019
- Completion date
- December 30, 2021
- Enrollment
- 5 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal carcinoma, metastatic colon adenocarcinoma, metastatic rectal adenocarcinoma, stage iii colon cancer ajcc v8, stage iii rectal cancer ajcc v8, stage iiia colon cancer ajcc v8, stage iiia rectal cancer ajcc v8, stage iiib colon cancer ajcc v8, stage iiib rectal cancer ajcc v8, stage iiic colon cancer ajcc v8, stage iiic rectal cancer ajcc v8, stage iv colon cancer ajcc v8, stage iv rectal cancer ajcc v8, stage iva colon cancer ajcc v8, stage iva rectal cancer ajcc v8, stage ivb colon cancer ajcc v8, stage ivb rectal cancer ajcc v8, stage ivc colon cancer ajcc v8, stage ivc rectal cancer ajcc v8, unresectable colon adenocarcinoma, unresectable rectal adenocarcinoma